Drug intelligence / Profile preview

Danhuang Lvxin capsule

Development stage: Unknown
Lead developer: Guizhou Yibai Pharmaceutical
Modality: Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
Administration: Oral

Overview

Danhuang Lvxin capsule is a traditional Chinese medicine (TCM) developed by Guizhou Baixiang Pharmaceutical Co., Ltd. for the treatment of chronic prostatitis. It is specifically indicated for patients presenting with the damp-heat downward flow pattern, a common TCM syndrome classification for prostatitis. The capsule is formulated to clear heat, resolve dampness, and alleviate symptoms associated with chronic inflammation of the prostate. It has been evaluated in randomized, double-blind, placebo-controlled Phase II clinical trials in China to assess its efficacy and safety in adult male patients.

Beyond the preview

Go deeper on Danhuang Lvxin capsule.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Danhuang Lvxin capsule.

Explore the full profile